{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:03:40Z","timestamp":1766181820694,"version":"3.41.2"},"reference-count":45,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: To circumvent possible systemic side effects, anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) for ocular neovascular diseases in adults are approved only for intravitreal administration. However, intravitreal injection itself can elicit injection-related adverse effects, and premature eyes of infants with retinopathy of prematurity (ROP) may be particularly susceptible to intravitreal injection. Therefore, an unmet clinical need is to develop safe systemic anti-angiogenic therapies for ROP. We recently reported that secretogranin III (Scg3) is a disease-restricted angiogenic factor and that systemic anti-Scg3 mAb alleviates ROP in animal models with minimal side effects on developing eyes and organs. The aim of this study is to investigate the safety and efficacy of a humanized anti-Scg3 antibody via systemic administration. Methods: We analyzed the safety and efficacy of a humanized anti-Scg3 antibody Fab fragment (hFab) delivered by intraperitoneal injection in oxygen-induced retinopathy (OIR) mice, a surrogate model of ROP. Results: The results showed that systemic anti-Scg3 hFab effectively alleviated pathological retinal neovascularization in OIR mice with similar efficacy to the anti-VEGF drug aflibercept. Systemic aflibercept conferred significant adverse side effects in neonatal mice, including reduced body weight, abnormalities in retinal and renal development, and retarded physiological neovascularization, whereas systemic anti-Scg3 hFab elicited no such side effects. Conclusions: The findings suggest that systemic anti-Scg3 hFab is a safe and effective therapy for OIR and support further development for ROP treatment.<\/jats:p>","DOI":"10.31083\/j.fbl2704130","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:53:52Z","timestamp":1650588832000},"source":"Crossref","is-referenced-by-count":5,"title":["Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy"],"prefix":"10.31083","volume":"27","author":[{"given":"Chang","family":"Dai","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tian","sequence":"first","affiliation":[{"name":"Everglades Biopharma, LLC, Houston, TX 77054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bhatt","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Texas Children Hospital, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanfang","family":"Su","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The Second Hospital of Jilin University, 130041 Changchun, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Webster","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Everglades Biopharma, LLC, Houston, TX 77054, USA"},{"name":"Vascular Biology Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Jefferies AL. Retinopathy of prematurity: an update on screening and management. Paediatrics & Child Health. 2016; 21: 101\u2013104.","key":"ref1","DOI":"10.1093\/pch\/21.2.101"},{"doi-asserted-by":"crossref","unstructured":"Dai C, Webster KA, Bhatt A, Tian H, Su G, Li W. Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies. International Journal of Molecular Sciences. 2021; 22: 4809.","key":"ref2","DOI":"10.3390\/ijms22094809"},{"doi-asserted-by":"crossref","unstructured":"Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015; 122: 200\u2013210.","key":"ref3","DOI":"10.1016\/j.ophtha.2014.07.050"},{"doi-asserted-by":"crossref","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O. Retinopathy of prematurity. The Lancet. 2013; 382: 1445\u20131457.","key":"ref4","DOI":"10.1016\/S0140-6736(13)60178-6"},{"doi-asserted-by":"crossref","unstructured":"Sukgen EA, Ko\u00e7luk Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology. 2019; 257: 49\u201355.","key":"ref5","DOI":"10.1007\/s00417-018-4168-5"},{"doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. The New England Journal of Medicine. 2011; 364: 603\u2013615.","key":"ref6","DOI":"10.1056\/NEJMoa1007374"},{"doi-asserted-by":"crossref","unstructured":"Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015; 35: 675\u2013680.","key":"ref7","DOI":"10.1097\/IAE.0000000000000578"},{"doi-asserted-by":"crossref","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019; 394: 1551\u20131559.","key":"ref8","DOI":"10.1016\/S0140-6736(19)31344-3"},{"doi-asserted-by":"crossref","unstructured":"Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99: 11946\u201311950.","key":"ref9","DOI":"10.1073\/pnas.182296499"},{"doi-asserted-by":"crossref","unstructured":"Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. The European Journal of Neuroscience. 2000; 12: 4243\u20134254.","key":"ref10","DOI":"10.1046\/j.0953-816X.2000.01326.x"},{"doi-asserted-by":"crossref","unstructured":"Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clinic Proceedings. 2012; 87: 77\u201388.","key":"ref11","DOI":"10.1016\/j.mayocp.2011.10.001"},{"doi-asserted-by":"crossref","unstructured":"Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. American Journal of Health-System Pharmacy. 2009; 66: 999\u20131013.","key":"ref12","DOI":"10.2146\/ajhp080455"},{"doi-asserted-by":"crossref","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013; 27: 787\u2013794.","key":"ref13","DOI":"10.1038\/eye.2013.107"},{"doi-asserted-by":"crossref","unstructured":"Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006; 113: 2002.e1\u20132002.12.","key":"ref14","DOI":"10.1016\/j.ophtha.2006.05.070"},{"doi-asserted-by":"crossref","unstructured":"LeBlanc ME, Wang W, Chen X, Caberoy NB, Guo F, Shen C, et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. The Journal of Experimental Medicine. 2017; 214: 1029\u20131047.","key":"ref15","DOI":"10.1084\/jem.20161802"},{"doi-asserted-by":"crossref","unstructured":"Tang F, LeBlanc ME, Wang W, Liang D, Chen P, Chou T, et al. Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety. Angiogenesis. 2019; 22: 369\u2013382.","key":"ref16","DOI":"10.1007\/s10456-019-09662-4"},{"doi-asserted-by":"crossref","unstructured":"Ji L, Waduge P, Hao L, Kaur A, Wan W, Wu Y, et al. Selectively targeting disease\u2010restricted secretogranin III to alleviate choroidal neovascularization. The FASEB Journal. 2022; 36: e22106.","key":"ref17","DOI":"10.1096\/fj.202101085RR"},{"doi-asserted-by":"crossref","unstructured":"Dai C, Waduge P, Ji L, Huang C, He Y, Tian H, et al. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy. Cellular and Molecular Life Sciences. 2022; 79: 63.","key":"ref18","DOI":"10.1007\/s00018-021-04111-2"},{"doi-asserted-by":"crossref","unstructured":"Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nature Protocols. 2009; 4: 1565\u20131573.","key":"ref19","DOI":"10.1038\/nprot.2009.187"},{"doi-asserted-by":"crossref","unstructured":"Stahl A, Chen J, Sapieha P, Seaward MR, Krah NM, Dennison RJ, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. The American Journal of Pathology. 2010; 177: 2715\u20132723.","key":"ref20","DOI":"10.2353\/ajpath.2010.100526"},{"doi-asserted-by":"crossref","unstructured":"Rojo Arias JE, Economopoulou M, Ju\u00e1rez L\u00f3pez DA, Kurzbach A, Au Yeung KH, Englmaier V, et al. VEGF\u2010Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy. Journal of Neurochemistry. 2020; 153: 390\u2013412.","key":"ref21","DOI":"10.1111\/jnc.14875"},{"doi-asserted-by":"crossref","unstructured":"Sapieha P. Eyeing central neurons in vascular growth and reparative angiogenesis. Blood. 2012; 120: 2182\u20132194.","key":"ref22","DOI":"10.1182\/blood-2012-04-396846"},{"doi-asserted-by":"crossref","unstructured":"Tanabe K, Wada J, Sato Y. Targeting angiogenesis and lymphangiogenesis in kidney disease. Nature Reviews Nephrology. 2020; 16: 289\u2013303.","key":"ref23","DOI":"10.1038\/s41581-020-0260-2"},{"doi-asserted-by":"crossref","unstructured":"Ahuja AA, V Reddy YC, Adenuga OO, Kewlani D, Ravindran M, Ramakrishnan R. Risk factors for retinopathy of prematurity in a district in South India: a prospective cohort study. Oman Journal of Ophthalmology. 2018; 11: 33\u201337.","key":"ref24","DOI":"10.4103\/ojo.OJO_97_2016"},{"unstructured":"Spires R. Retinopathy of prematurity. Journal of Ophthalmic Nursing & Technology. 1991; 10: 166\u2013170.","key":"ref25"},{"doi-asserted-by":"crossref","unstructured":"Lutty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Investigative Ophthalmology & Visual Science. 2011; 52: 4039\u20134047.","key":"ref26","DOI":"10.1167\/iovs.10-6798"},{"doi-asserted-by":"crossref","unstructured":"Tokunaga CC, Mitton KP, Dailey W, Massoll C, Roumayah K, Guzman E, et al. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Investigative Ophthalmology & Visual Science. 2014; 55: 1884\u20131892.","key":"ref27","DOI":"10.1167\/iovs.13-13397"},{"doi-asserted-by":"crossref","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014; 121: 2212\u20132219.","key":"ref28","DOI":"10.1016\/j.ophtha.2014.05.015"},{"doi-asserted-by":"crossref","unstructured":"Vogel RN, Strampe M, Fagbemi OE, Visotcky A, Tarima S, Carroll J, et al. Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmology. 2018; 125: 444\u2013452.","key":"ref29","DOI":"10.1016\/j.ophtha.2017.09.020"},{"doi-asserted-by":"crossref","unstructured":"Clark A, Wright T, Isaac M, Westall C, Mireskandari K, Tehrani NN. Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity: an OCT study. Journal of AAPOS. 2017; 21: 499\u2013501.e1.","key":"ref30","DOI":"10.1016\/j.jaapos.2017.06.024"},{"doi-asserted-by":"crossref","unstructured":"Wu W, Shih C, Lien R, Wang N, Chen Y, Chao A, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017; 37: 694\u2013701.","key":"ref31","DOI":"10.1097\/IAE.0000000000001209"},{"doi-asserted-by":"crossref","unstructured":"Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE. 2020; 15: e0230678.","key":"ref32","DOI":"10.1371\/journal.pone.0230678"},{"doi-asserted-by":"crossref","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard M, et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016; 137: e20153218.","key":"ref33","DOI":"10.1542\/peds.2015-3218"},{"doi-asserted-by":"crossref","unstructured":"Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Archives of Ophthalmology. 1997; 115: 741\u2013747.","key":"ref34","DOI":"10.1001\/archopht.1997.01100150743009"},{"doi-asserted-by":"crossref","unstructured":"V\u00e9steinsd\u00f3ttir E, Bj\u00f6rnsd\u00f3ttir S, Hreidarsson AB, Stef\u00e1nsson E. Risk of retinal neovascularization in the second eye in patients with proliferative diabetic retinopathy. Archives of Ophthalmology. 2010; 88: 449\u2013452.","key":"ref35","DOI":"10.1111\/j.1755-3768.2008.01440.x"},{"doi-asserted-by":"crossref","unstructured":"Nuzzi R, Tridico F. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. Seminars in Ophthalmology. 2015; 30: 129\u2013135.","key":"ref36","DOI":"10.3109\/08820538.2013.835833"},{"doi-asserted-by":"crossref","unstructured":"Kingsley DM, Rinchik EM, Russell LB, Ottiger HP, Sutcliffe JG, Copeland NG, et al. Genetic ablation of a mouse gene expressed specifically in brain. The EMBO Journal. 1990; 9: 395\u2013399.","key":"ref37","DOI":"10.1002\/j.1460-2075.1990.tb08123.x"},{"doi-asserted-by":"crossref","unstructured":"Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O\u2019Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996; 380: 439\u2013442.","key":"ref38","DOI":"10.1038\/380439a0"},{"doi-asserted-by":"crossref","unstructured":"Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995; 376: 66\u201370.","key":"ref39","DOI":"10.1038\/376066a0"},{"doi-asserted-by":"crossref","unstructured":"Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995; 376: 62\u201366.","key":"ref40","DOI":"10.1038\/376062a0"},{"doi-asserted-by":"crossref","unstructured":"Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. The American Journal of Pathology. 2003; 163: 879\u2013887.","key":"ref41","DOI":"10.1016\/S0002-9440(10)63448-7"},{"doi-asserted-by":"crossref","unstructured":"Yang Z, Wang H, Jiang Y, Hartnett ME. VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. The American Journal of Pathology. 2014; 184: 1230\u20131239.","key":"ref42","DOI":"10.1016\/j.ajpath.2013.12.023"},{"doi-asserted-by":"crossref","unstructured":"Mezu-Ndubuisi OJ, Song YS, Macke E, Johnson H, Nwaba G, Ikeda A, et al. Retinopathy of prematurity shows alterations in Vegfa_\u2062164 isoform expression. Pediatric Research. 2021. (in press)","key":"ref43","DOI":"10.1038\/s41390-021-01646-9"},{"doi-asserted-by":"crossref","unstructured":"Sun J, Huang W, Yang S, Zhang X, Yu Q, Zhang Z, et al. G\u03b1i1 and G\u03b1i3mediate VEGF-induced VEGFR2 endocytosis, signaling and angiogenesis. Theranostics. 2018; 8: 4695\u20134709.","key":"ref44","DOI":"10.7150\/thno.26203"},{"doi-asserted-by":"crossref","unstructured":"Budd SJ. Increased Angiogenic Factors Associated with Peripheral Avascular Retina and Intravitreous Neovascularization. Archives of Ophthalmology. 2010; 128: 589.","key":"ref45","DOI":"10.1001\/archophthalmol.2010.65"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/4\/10.31083\/j.fbl2704130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:58:59Z","timestamp":1732708739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/4\/10.31083\/j.fbl2704130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00471-3"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2704130","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"type":"print","value":"2768-6701"},{"type":"electronic","value":"2768-6698"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"article-number":"130"}}